Clinical Study
The Modification Effect of Influenza Vaccine on Prognostic Indicators for Cardiovascular Events after Acute Coronary Syndrome: Observations from an Influenza Vaccination Trial

Apirak Sribhutorn,1,2 Arintaya Phrommintikul,3 Wanwarang Wongcharoen,3 Usa Chaikledkaew,4 Suntara Eakanunkul,5 and Apichard Sukonthasarn3

1Ph.D. Program in Clinical Epidemiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
2Department of Pharmacy Practice, School of Pharmaceutical Sciences, University of Phayao, Phayao 56000, Thailand
3Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
4Social and Administrative Pharmacy Excellence Research (SAPER) Unit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand
5Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand

Correspondence should be addressed to Arintaya Phrommintikul; arintayap@gmail.com

Received 9 March 2016; Accepted 29 March 2016

Academic Editor: Mariantonietta Cicoira

Copyright © 2016 Apirak Sribhutorn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. The prognosis of acute coronary syndrome (ACS) patients has been improved with several treatments such as antithrombotics, beta-blockers, and angiotensin-converting enzyme inhibitors (ACEI) as well as coronary revascularization. Influenza vaccination has been shown to reduce adverse outcomes in ACS, but no information exists regarding the interaction of other treatments.

Methods. This study included 439 ACS patients from Phrommintikul et al. A single dose of inactivated influenza vaccine was given by intramuscular injection in the vaccination group. The cardiovascular outcomes were described as major cardiovascular events (MACEs) which included mortality, hospitalization due to ACS, and hospitalization due to heart failure (HF). The stratified and multivariable Cox’s regression analysis was performed. Results. The stratified Cox’s analysis by influenza vaccination for each cardiovascular outcome and discrimination of hazard ratios showed that beta-blockers had an interaction with influenza vaccination. Moreover, the multivariable hazard ratios disclosed that influenza vaccine is associated with a significant reduction of hospitalization due to HF in patients who received beta-blockers (HR = 0.05, 95% CI = 0.004–0.71, P = 0.027), after being adjusted for prognostic indicators (sex, dyslipidemia, serum creatinine, and left ventricular ejection fraction). Conclusions. The influenza vaccine was shown to significantly modify the effect of beta-blockers in ACS patients and to reduce the hospitalization due to HF. However, further study of a larger population and benefits to HF patients should be investigated.

1. Introduction

Influenza vaccination in the community can significantly reduce influenza infection [1] and incidence of influenza-like illness among the elderly [2], as well as hospitalization and death due to pneumonia, influenza [3–7], or cardiovascular diseases [1, 3–8]. Furthermore, randomized controlled studies have demonstrated benefits in reducing major adverse cardiovascular events among patients with coronary artery diseases (CAD) [9–13]. For this reason, the American Heart Association and American College of Cardiology recommend influenza vaccination as a secondary prevention intervention in patients with CAD and atherosclerotic vascular diseases [14, 15] and those with ST-segment elevation myocardial infarction (STEMI) [16] and unstable angina/non-STEMI [17] as well as a plan of care for patients with chronic heart failure [18].

Nonetheless, the evidence-based recommendations and benefits of influenza vaccination have been shown in CAD; the mechanisms of its benefit have not yet been defined,
as well as some queries on the vaccine immunological response in patients with various clinical characteristics, such as impaired renal function or concurrent medications [19–22]. The study of prognostic indicators and patients’ clinical characteristics may describe the benefits of influenza vaccine for cardiovascular outcomes.

An annual influenza vaccination can prevent influenza virus infection and relieve the symptoms of acute infection. In fact, an annual influenza vaccination can prevent influenza infection and also decrease the results from acute infection, where it promotes inflammation and the progression of atherosclerosis and it serves as a trigger for acute myocardial infarction [23–29]. Consequently, the administration of influenza vaccine may reveal an influence on some prognostic indicators for cardiovascular outcomes, compared with patients not receiving the vaccination.

Therefore, this study aimed to explore the effects of the influenza vaccine through the prognostic indicators for each cardiovascular outcome among ACS patients.

2. Patients and Methods

2.1. Data Sources and Data Collection. This observational study was based on a prospective, randomized open with blinded endpoint study from Phrommintikul et al. [9], which enrolled 439 patients who had been admitted due to ACS and were older than 50 years old. Patients were excluded if they had hemoglobin level lower than 10 g/dL, elevated serum creatinine (Scr) level more than 2.5 mg/dL, well-established liver disease, cancer or life expectancy less than one year, and contraindications to, or previous, influenza vaccination. All patients were given standard treatment by their primary cardiologist in the tertiary care hospital of Chiang Mai University.

2.2. Definition. The ACS patients were classified into three groups. These included the following: (1) patients with an acute ST-segment elevation myocardial infarction (STEMI) described as a chest pain lasting longer than 20 minutes with ST-segment elevation of electrocardiograph (EKG) in two consecutive leads or more, (2) patients with chest pain lasting longer than 20 minutes, with rising of cardiac troponin or CK-MB and without ST-segment elevation EKG, defined as non-ST-segment elevation myocardial infarction (NSTEMI), and (3) patients with chest pain at rest without rising of cardiac troponin or CK-MB, diagnosed as an unstable angina (UA), whereas NSTEMI and UA were defined as non-ST-segment elevation ACS (NSTEMACS).

The studied patients’ characteristics included age, sex, concurrent comorbidities, that is, hypertension (HT); diabetes mellitus (DM); dyslipidemia; chronic obstructive pulmonary disease (COPD); smoking; prior myocardial infarction (MI); chronic kidney disease (CKD); Scr, type of ACS, revascularization procedure, left ventricular ejection fraction (LVEF), and medications.

The main cardiovascular outcomes of interest were defined as (1) major adverse cardiovascular events (MACEs), a composite of all cardiovascular events, (2) all causes of mortality, (3) hospitalization due to acute coronary syndrome (ACS), (4) hospitalization due to heart failure (HF), and (5) composite outcomes of hospitalization (ACS, HF, or stroke). These outcomes were verified by cardiologists during the follow-up of 12 months. Survival status of patients lost to follow-up was determined by telephone.

2.3. Data Analysis. The patients’ characteristics were compared among five types of adverse cardiovascular outcomes and each outcome-free group, using Fisher's exact test, where multiple imputations were manipulated for missing data management.

Prognostic indicators for each cardiovascular outcome were stratified by influenza vaccine groups and analyzed as multivariable hazard ratio by the stratified Cox regression. The Z-test was performed to demonstrate significant discrimination of hazard ratio between influenza vaccination groups [30]. Multivariable Cox's regression was conducted to present the results, subsequently adjusted for independent prognostic indicators of each cardiovascular outcome.

This study was approved by the Ethics Committee, Faculty of Medicine, Chiang Mai University.

3. Results

3.1. Patients’ Characteristics. In this observational study, data of 439 ACS patients were collected. Half of the patients were older than 65 years old and 56.7% of the patients (249) were males (Table 1). HT was present among 265 (60.4%); DM, 134 (30.5%); dyslipidemia, 206 (46.9%); COPD, 13 (3.0%); and CKD, 20 (4.56%). Regarding the index ACS, STEMI and NSTEMIACS were present among 159 (36.2%) and 280 (63.8%) of the patients, respectively. The majority of STEMI patients (79.25%) received reperfusion therapy and more than a half of the NSTEMIACS patients (53.21%) received coronary revascularization. Aspirin, beta-blockers, and statin were received among 427 (97.3%), 325 (74.0%), and 293 (66.7%) patients, respectively.

3.2. Prognostic Indicators of Adverse Outcomes. The characteristics of ACS patients with and without MACEs were not significantly different, except for dyslipidemia, LVEF, receiving angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), and influenza vaccination (Table 1). Patients with MACEs had higher proportion of dyslipidemia (61.3% versus 44.6%, \( P = 0.019 \)) but a lower proportion of receiving ACE-I/ARB (45.2% versus 60.7%, \( P = 0.026 \)) and influenza vaccination (33.9% versus 53.1%, \( P = 0.006 \)). The MACEs-free patients also had a great proportion of preserved LVEF (LVEF > 40%) (70.8% versus 51.6%, \( P = 0.005 \)) (Table 1).

Regarding the causes of death, patients who survived were younger (age 65 ± 9.17 versus 73.0 ± 9.29 years, \( P = 0.0014 \)). The other clinical characteristics did not significantly differ between two groups (Table 1).

When comparing between patients with composite outcomes of hospitalization due to ACS, HF, or stroke and those who were not hospitalized (Table 2), patients with these events had a higher proportion of dyslipidemia (63.3% versus...
Cardiology Research and Practice

Table 1: Patients’ characteristics for MACEs and death.

| Characteristics | Total (n = 439) | Event-free (A) (n = 377) | MACEs (n = 62) | P value | Survived (n = 421) | Death (n = 18) | P value |
|-----------------|----------------|---------------------------|----------------|---------|--------------------|--------------|---------|
| Age (year)      |                |                           |                |         |                    |              |         |
| ≤65             | 219            | 49.9%                     | 25             | 40.3%   | 0.131              | 216          | 51.3%   | 3       | 16.7% | 0.006       |
| >65             | 220            | 50.1%                     | 37             | 59.7%   |                    | 205          | 48.7%   | 15      | 83.3% |              |
| Male            | 249            | 56.7%                     | 31             | 50.0%   | 0.270              | 243          | 57.7%   | 6       | 33.3% | 0.052       |
| HT              | 265            | 60.4%                     | 43             | 69.4%   | 0.126              | 252          | 59.9%   | 13      | 72.2% | 0.336       |
| DM              | 134            | 30.5%                     | 21             | 33.8%   | 0.533              | 127          | 30.2%   | 7       | 38.9% | 0.440       |
| Dyslipidemia    | 206            | 46.9%                     | 38             | 61.3%   | 0.019              | 197          | 46.8%   | 9       | 50.0% | 0.814       |
| COPD            | 13             | 3.0%                      | 2              | 3.2%    | 1.000              | 13           | 3.1%    | 0       | 0.0%  | 1.000       |
| Smoking         | 48             | 11.0%                     | 3              | 4.8%    | 0.123              | 48           | 11.4%   | 0       | 0.0%  | 0.241       |
| Prior MI        | 18             | 4.1%                      | 15             | 4.0%    | 0.729              | 18           | 4.3%    | 0       | 0.0%  | 1.000       |
| CKD             | 20             | 4.6%                      | 5              | 8.1%    | 0.181              | 20           | 4.8%    | 0       | 0.0%  | 1.000       |
| Scr (mg/dL)     |                |                           |                |         |                    |              |         |
| ≤1.1            | 221            | 50.3%                     | 27             | 43.6%   | 0.274              | 212          | 50.4%   | 9       | 50.0% | 1.000       |
| >1.1            | 218            | 49.7%                     | 35             | 56.5%   |                    | 209          | 49.6%   | 9       | 50.0% |              |
| Type of ACS     |                |                           |                |         |                    |              |         |
| NSTEMI & UA     | 280            | 63.8%                     | 38             | 61.3%   | 0.671              | 272          | 64.6%   | 8       | 44.4% | 0.130       |
| STEMI           | 159            | 36.2%                     | 24             | 38.7%   |                    | 149          | 35.4%   | 10      | 55.6% |              |
| Reperfusion or revascularization |     |                           |                |         |                    |              |         |
| No              | 164            | 37.4%                     | 23             | 37.1%   | 1.000              | 158          | 37.3%   | 6       | 33.3% | 0.808       |
| Yes             | 275            | 62.6%                     | 39             | 62.9%   |                    | 263          | 62.5%   | 12      | 66.7% |              |
| LVEF (%)        |                |                           |                |         |                    |              |         |
| >40             | 299            | 68.1%                     | 32             | 51.6%   | 0.005              | 290          | 68.9%   | 9       | 50.0% | 0.120       |
| ≤40             | 140            | 31.9%                     | 30             | 48.4%   |                    | 131          | 31.1%   | 9       | 50.0% |              |
| Medication      |                |                           |                |         |                    |              |         |
| Aspirin         | 427            | 97.3%                     | 61             | 98.4%   | 1.000              | 409          | 97.2%   | 18      | 100.0%| 1.000       |
| β-blocker       | 325            | 74.0%                     | 44             | 71.0%   | 0.536              | 311          | 73.9%   | 14      | 77.8% | 1.000       |
| CCB             | 72             | 16.4%                     | 9              | 14.5%   | 0.853              | 69           | 16.4%   | 3       | 16.7% | 1.000       |
| ACE-I/ARB       | 257            | 58.5%                     | 28             | 45.2%   | 0.026              | 250          | 59.4%   | 7       | 38.9% | 0.093       |
| Statin          | 293            | 66.7%                     | 41             | 66.1%   | 1.000              | 283          | 67.2%   | 10      | 55.6% | 0.315       |
| Influenza vaccine | 221          | 50.3%                     | 21             | 33.9%   | 0.006              | 215          | 51.1%   | 6       | 33.3% | 0.156       |

DM, diabetes mellitus; HT, hypertension; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; CKD, chronic kidney disease; Scr, serum creatinine; ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; LVEF, left ventricular ejection fraction; CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; MACEs, major adverse cardiovascular events; event-free (A), free events from MACEs.

44.9%, \( P = 0.022 \) and impaired LVEF (LVEF < 40%) (49.0% versus 29.7%, \( P = 0.009 \)). They also had low proportion of influenza vaccination (32.7% versus 52.6%, \( P = 0.010 \)) (Table 2).

The comparison of three outcomes among those hospitalized due to ACS, HF, and event-free patients revealed significant differences in proportion of dyslipidemia (58.9%, 78.6%, and 44.8%, respectively, \( P = 0.017 \)), CKD (2.9%, 28.6%, and 3.8%, respectively, \( P = 0.004 \)), impaired LVEF (35.3%, 78.6%, and 29.9%, respectively, \( P = 0.001 \)), and influenza vaccination (32.35%, 28.6%, and 52.69%, respectively, \( P = 0.020 \)) (Table 2). Interestingly, patients hospitalized due to HF had a high proportion of dyslipidemia (78.6%, \( P = 0.017 \)), presented CKD (28.6%, \( P = 0.004 \)), and impaired LVEF (78.6%, \( P = 0.001 \)) but revealed a lower proportion of receiving influenza vaccination (28.6%, \( P = 0.020 \)).

When stratified Cox’s regression analysis by influenza vaccine group was performed for each cardiovascular outcome (Table 3), the significant protective indicator was receiving ACE-I/ARB, while impaired LVEF, age above 65 years, and CKD presented poor indicators in the nonvaccination group.

The impaired LVEF variables were shown as poor prognostic indicators in both groups of patients with similar
Table 2: Patients’ characteristics of composite outcomes of hospitalization (ACS, HF, or stroke), hospitalization due to ACS, and hospitalization due to HF.

| Characteristics     | Event-free (B) (n = 390) | Composite hospitalization (n = 49) | P value | Event-free (C) (n = 391) | Hospitalization due to ACS (n = 34) | Hospitalization due to HF (n = 14) | P value |
|---------------------|---------------------------|------------------------------------|---------|------------------------|------------------------------------|-----------------------------------|---------|
|                     | n (%)                     | n (%)                              |         | n (%)                  | n (%)                              | n (%)                            |         |
| Age (year)          |                           |                                    |         |                        |                                    |                                   |         |
| ≤65                 | 196 (50.3)                | 23 (46.9)                          | 0.762   | 197 (50.4)             | 17 (50.0)                          | 5 (35.7)                          | 0.616   |
| >65                 | 194 (49.7)                | 26 (53.1)                          |         | 194 (49.6)             | 17 (50.0)                          | 9 (64.3)                          |         |
| Male                | 223 (57.2)                | 26 (53.1)                          | 0.647   | 224 (57.3)             | 20 (58.8)                          | 5 (35.7)                          | 0.306   |
| HT                  | 231 (59.2)                | 34 (69.4)                          | 0.215   | 232 (59.3)             | 23 (67.7)                          | 10 (71.4)                         | 0.495   |
| DM                  | 116 (29.7)                | 18 (36.7)                          | 0.326   | 116 (29.7)             | 11 (32.4)                          | 7 (50.0)                          | 0.242   |
| Dyslipidemia        | 175 (44.9)                | 31 (63.3)                          | 0.022   | 175 (44.8)             | 20 (58.8)                          | 11 (78.6)                         | 0.017   |
| COPD                | 11 (2.8)                  | 2 (4.1)                            | 0.646   | 12 (3.1)               | 0 (0.0)                            | 1 (7.1)                           | 0.286   |
| Smoking             | 45 (11.5)                 | 3 (6.1)                            | 0.335   | 45 (11.5)              | 3 (8.8)                            | 0 (0.0)                           | 0.491   |
| Prior MI            | 15 (3.9)                  | 3 (6.1)                            | 0.439   | 15 (3.8)               | 1 (2.9)                            | 2 (14.3)                          | 0.147   |
| CKD                 | 15 (3.9)                  | 5 (10.2)                           | 0.060   | 15 (3.8)               | 1 (2.9)                            | 4 (28.6)                          | 0.004   |
| SCr (mg/dL)         |                           |                                    |         |                        |                                    |                                   |         |
| ≤1.1                | 201 (51.5)                | 20 (40.8)                          | 0.174   | 202 (51.7)             | 16 (47.1)                          | 3 (21.4)                          | 0.077   |
| >1.1                | 189 (48.5)                | 29 (59.2)                          |         | 189 (48.3)             | 18 (52.9)                          | 11 (78.6)                         |         |
| Type of ACS         |                           |                                    |         |                        |                                    |                                   |         |
| NSTEMI & UA         | 247 (63.3)                | 33 (67.4)                          | 0.639   | 248 (63.4)             | 22 (64.7)                          | 10 (71.4)                         | 0.907   |
| STEMI               | 143 (36.7)                | 16 (32.7)                          |         | 143 (36.6)             | 12 (35.3)                          | 4 (28.6)                          |         |
| Reperfusion or revascularization |       |                                    |         |                        |                                    |                                   |         |
| No                  | 146 (37.4)                | 18 (36.7)                          | 1.000   | 146 (37.3)             | 9 (26.5)                           | 9 (64.3)                          | 0.054   |
| Yes                 | 244 (62.6)                | 31 (63.3)                          |         | 245 (62.7)             | 25 (73.5)                          | 5 (35.7)                          |         |
| LVEF (%)            |                           |                                    |         |                        |                                    |                                   |         |
| >40                 | 274 (70.3)                | 25 (51.0)                          | 0.009   | 274 (70.1)             | 22 (64.7)                          | 3 (21.4)                          | 0.001   |
| ≤40                 | 116 (29.7)                | 24 (49.0)                          |         | 117 (30.0)             | 12 (35.3)                          | 11 (78.6)                         |         |
| Medication          |                           |                                    |         |                        |                                    |                                   |         |
| Aspirin             | 379 (97.2)                | 48 (98.0)                          | 1.000   | 380 (97.2)             | 33 (97.1)                          | 14 (100.0)                        | 1.000   |
| β-blocker           | 291 (74.6)                | 34 (69.4)                          | 0.489   | 291 (74.4)             | 25 (73.5)                          | 9 (64.3)                          | 0.676   |
| CCB                 | 65 (16.7)                 | 7 (14.3)                           | 0.838   | 65 (16.6)              | 5 (14.7)                           | 2 (14.3)                          | 1.000   |
| ACE-I/ARB           | 234 (60.0)                | 23 (47.0)                          | 0.091   | 235 (60.1)             | 17 (50.0)                          | 5 (35.7)                          | 0.121   |
| Statin              | 259 (66.4)                | 34 (69.4)                          | 0.749   | 260 (66.5)             | 24 (70.6)                          | 9 (64.3)                          | 0.872   |
| Influenza vaccination | 205 (52.6)                | 16 (32.7)                          | 0.010   | 206 (52.7)             | 11 (32.4)                          | 4 (28.6)                          | 0.020   |

DM, diabetes mellitus; HT, hypertension; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; CKD, chronic kidney disease; SCr, serum creatinine; HF, heart failure; ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; LVEF, left ventricular ejection fraction; CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; Composite hospitalization, composite hospitalization due to ACS, HF, or stroke; event-free (B), free events from composite hospitalization due to ACS, HF, or stroke; event-free (C), free events from hospitalization due to ACS or HF.

hazard ratios (Tables 3 and 4). Age above 65 years was indicated as a significant prognostic indicator for death in the nonvaccination group (HR = 10.78, 95% CI = 1.39–83.62, P = 0.023) but not in the vaccination group (HR = 2.28, 95% CI = 0.42–12.48, P = 0.341). However, the effect size of age did not significantly vary between vaccination groups (P = 0.252) (Table 4). Differently, the CKD variable was a promising poor prognostic indicator in both groups, (HR = 5.12, 95% CI = 1.27–20.65, P = 0.022) and (HR = 24.01, 95% CI = 1.34–417.20, P = 0.029). However, the effect size of CKD hazard ratio seemed to diverge with a wide range of confidence intervals; a significant difference was not demonstrated (P = 0.340) (Table 4).
Table 3: Multivariable hazard ratios stratified by influenza vaccination for each cardiovascular event, which was analyzed by multivariable stratified Cox’s regression analysis.

| Prognostic indicators | No vaccination | Influenza vaccination |
|-----------------------|----------------|-----------------------|
|                       | HR (95% CI)    | P value               | HR (95% CI)    | P value               |
| MACEs                 |                |                       |                |                       |
| LVEF (%)              |                |                       |                |                       |
| ≤40                   | 2.07 (1.12–3.82) | 0.021                 | 2.37 (1.01–5.59) | 0.048                 |
| Medication            |                |                       |                |                       |
| ACE-I/ARB             | 0.44 (0.23–0.83) | 0.012                 | 1.12 (0.45–2.78) | 0.806                 |
| Death                 |                |                       |                |                       |
| Age (year)            |                |                       |                |                       |
| >65                   | 10.78 (1.39–83.62) | 0.023                 | 2.28 (0.42–12.48) | 0.341                 |
| Medication            |                |                       |                |                       |
| ACE-I/ARB             | 0.26 (0.07–0.94) | 0.041                 | 1.15 (0.21–6.30) | 0.870                 |
| Composite hospitalization due to ACS, HF, or stroke | | | |
| LVEF (%)              |                |                       |                |                       |
| ≤40                   | 2.25 (1.14–4.45) | 0.020                 | 2.16 (0.81–5.76) | 0.124                 |
| Medication            |                |                       |                |                       |
| ACE-I/ARB             | 0.48 (0.24–0.99) | 0.046                 | 1.23 (0.43–3.54) | 0.701                 |
| Hospitalization due to ACS | No indicator was found | | | |
| Hospitalization due to HF | | | | |
| CKD                   | 5.12 (1.27–20.65) | 0.022                 | 24.01 (1.38–417.20) | 0.029                 |
| LVEF (%)              |                |                       |                |                       |
| ≤40                   | 7.93 (1.63–38.66) | 0.010                 | 8.37 (0.72–97.72) | 0.090                 |
| Medication            |                |                       |                |                       |
| Beta-blocker          | 1.63 (0.34–7.78) | 0.542                 | 0.05 (0.003–0.76) | 0.037                 |

MACEs, major adverse cardiovascular events; LVEF, left ventricular ejection fraction; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ACS, acute coronary syndrome; HF, heart failure; CKD, chronic kidney disease.

protective indicator in the vaccination group (HR = 0.05, 95% CI = 0.003–0.76, \( P = 0.037 \)) (Table 3). Moreover, the comparison of hazard ratio between vaccination groups indicated a remarkable difference (\( P = 0.03 \)) (Table 4).

In summary, the influenza vaccination influenced the prognostic value of clinical predictors for each cardiovascular outcome when compared with nonvaccination group, except two predictors of impaired LVEF for MACEs (HR = 2.07, 95% CI = 1.12–3.82, \( P = 0.021 \) and HR = 2.37, 95% CI = 1.01–5.59, \( P = 0.048 \)) and CKD for hospitalization due to HF (HR = 5.12, 95% CI = 1.27–20.65, \( P = 0.022 \) and HR = 24.01, 95% CI = 1.34–417.20, \( P = 0.029 \)). However, no significant difference was observed of hazard ratios between influenza vaccination groups, but receiving beta-blockers revealed the differences (\( P = 0.030 \)) (Table 4).

Multivariable Cox’s regression (Table 5) demonstrated that influenza vaccination and beta-blockers coadministration indicated a potential protective effect (HR = 0.05, 95% CI = 0.004–0.71, \( P = 0.027 \)) after adjusting for sex, dyslipidemia, CKD, SCr, and LVEF, but both factors were independent prognostic indicators for hospitalization due to HF.

The interaction of influenza vaccination among patients receiving beta-blockers was described by a significant reduction of the hazard ratio among patients who had vaccination.
Table 4: Discrimination of multivariable hazard ratios by the influenza vaccination for each cardiovascular event.

| Prognostic indicators | No vaccination | Influenza vaccination | Z   | P value |
|-----------------------|----------------|-----------------------|-----|---------|
|                       | HR (95% CI)    | HR (95% CI)           |     |         |
| MACEs                 |                |                       |     |         |
| LVEF (%)              |                |                       |     |         |
| ≤40                   | 2.07 (1.12–3.82)| 2.37 (1.01–5.59)     | −0.26| 0.797   |
| Medication            |                |                       |     |         |
| ACE-I/ARB             | 0.44 (0.23–0.83)| 1.12 (0.45–2.78)     | −1.65| 0.098   |
| Death                 |                |                       |     |         |
| Age (year)            |                |                       |     |         |
| >65                   | 10.78 (1.39–83.62)| 2.28 (0.42–12.48)   | 1.14 | 0.252   |
| Medication            |                |                       |     |         |
| ACE-I/ARB             | 0.26 (0.07–0.94)| 1.15 (0.21–6.30)    | −1.38| 0.169   |
| Composite hospitalization due to ACS, HF, or stroke | | | | |
| LVEF (%)              |                |                       |     |         |
| ≤40                   | 2.25 (1.14–4.45)| 2.16 (0.81–5.76)     | 0.07 | 0.948   |
| Medication            |                |                       |     |         |
| ACE-I/ARB             | 0.48 (0.24–0.99)| 1.23 (0.43–3.54)     | −1.43| 0.152   |
| Hospitalization due to ACS | | | | |
| No indicator was found| | | | |
| Hospitalization due to HF | | | | |
| CKD                   | 5.12 (1.27–20.65)| 24.01 (1.38–417.20) | −0.95| 0.340   |
| LVEF (%)              |                |                       |     |         |
| ≤40                   | 7.93 (1.63–38.66)| 8.37 (0.72–97.72)    | −0.04| 0.971   |
| Medication            |                |                       |     |         |
| Beta-blocker          | 1.63 (0.34–7.78)| 0.05 (0.003–0.76)    | 2.18 | 0.030   |

MACEs, major adverse cardiovascular events; LVEF, left ventricular ejection fraction; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ACS, acute coronary syndrome; HF, heart failure; CKD, chronic kidney disease.

Table 5: Multivariable hazard ratios and 95% confidence intervals of influenza vaccination and beta-blocker for hospitalization due to HF.

| Influenza vaccine | Beta-blocker | HR   | 95% CI  | P value |
|-------------------|--------------|------|---------|---------|
| No                | No           | Reference |       |         |
| No                | Yes          | 1.29 | 0.27–6.16| 0.750   |
| Yes               | No           | 2.46 | 0.40–15.22| 0.334   |
| Yes               | Yes          | 0.05 | 0.01–0.71| 0.027   |

Note: All analyses were adjusted for gender, dyslipidemia, SCr, and LVEF, which are independent prognostic indicators for hospitalization due to HF.

4. Discussion

This post hoc study demonstrated that the significant prognostic indicators for cardiovascular events in patients with ACS were age, LVEF, CKD, and receiving ACE-I/ARB. Even though the hazard ratio of each individual prognostic factor may differ between the vaccination and nonvaccination groups, the difference was not significant, except for receiving beta-blockers. Receiving beta-blockers presented the prognostic indicator for the reduction of hospitalization due to HF when influenza vaccine was given.

The evidence from seasonal patterns of cardiovascular deaths was similar to patterns of influenza circulation [29]. Clinical findings among patients with influenza presented systemic effects such as myalgia, high fever, and fatigue, as well as frequent myocardial involvement [29]. The influenza
virus has extensive effects on the inflammatory and coagulation pathways, leading to destabilization of vulnerable atherosclerotic plaques and coronary occlusion, which are major causes of acute MI [29]. Moreover, host response to acute infections can facilitate ACS by affecting coronary arteries and atherosclerotic lesions, such as increased sympathetic activity [28].

The upregulated sympathetic nervous system shown in heart failure [18] may reduce the influenza vaccine response [31–33] or cause persistence decline of antibody titers [32].

The sympathetic nervous system will increase proinflammatory cytokines and exacerbate influenza infection, as shown in animal models [34]. In the lung of infected animals, the anti-influenza CD8+ T cell response could be limited by sympathetic nervous system [35], while cytotoxic T lymphocytes could effectively respond to different subtypes of influenza virus with a specific antibody response [36]. Cytotoxic T cells were described as important factors for recovering from influenza infection in humans [36].

Human T and B lymphocytes express beta-2 adrenergic receptors, where the catecholamine effect via beta-2 adrenergic receptors on cytokine regulation decreased responses to vaccines [37]. In contrast, T cell responses were enhanced by the administration of beta-2 adrenergic antagonists [35].

The study in mice showed that acute stress reduced the number of NK cells in the intraparenchymal region of the lungs and this event could be reversed by the administration of beta-adrenergic antagonists [38]. Acute stress can be hypothesized as the cause of lung lymphocyte redistribution through beta-adrenergic stimulation by elevating catecholamine level [38]. Therefore, beta-blockers could reduce the inflammatory response and the degree of lung injury. Some animal models revealed survival benefits, particularly when beta-blockers were administered before the septic insult [39].

Beta-blockers are recommended as a secondary prevention for ACS patients recovering from acute MI and without contraindication [40]. ACS was indicated as an important cause of worsening or new-onset of HF and also a common factor precipitating acute decompensated HF [18]. Consequently, prescribing beta-blockers to chronic HF patients is recommended due to their protective results [18, 41].

The decrease in heart rate, contractility, and blood pressure due to beta-blockers could inhibit the effects of circulating catecholamines and oxygen demand [42]. Beta-blockers can reduce the sympathetic tone by inhibiting an increase in catecholamine circulation [43], as a cause of proinflammatory cytokines [34, 43] and disrupt the immune response [43].

Moreover, the administration of influenza vaccine can prevent influenza infection and also reduce acute infection effects by promoting inflammation, the progression of atherosclerosis, and triggering acute MI [9–15, 17].

In this study, solely administration of beta-blockers or influenza vaccination was not shown to be the protective evidence for hospitalization due to HF among ACS patients. However, the combination of the two showed very synergistic effect during a year of follow-up time.

4.1. Limitation. Incomplete data was a limitation of this study. Only 2 incomplete variables were found from 20 variables. The variables of SCr and LVEF had 6.83% and 54.67% of missing values, respectively. However, multiple imputations were conducted and imputed data were categorized for appropriate data management.

5. Conclusion

The study showed that influenza vaccination influenced the prognostic abilities of clinical predictors for cardiovascular outcomes when compared between patients who received vaccination and the nonvaccination group. However, two predictors of impaired LVEF for MACEs and CKD for hospitalization due to HF were not affected. Moreover, different prognostic ability between influenza vaccination groups was not significantly observed, but receiving beta-blockers was acknowledged.

This study presented the strong modification effect of influenza vaccine among ACS patients who received beta-blockers to reduce hospitalization due to HF. This benefit of influenza vaccination should be noteworthy considered in clinical practice for ACS patients. However, further studies of influenza vaccine and beta-blocker synergy should be established in a larger population involving clinical trials. Although, this study disclosed a new benefit of influenza vaccine and beta-blockers coadministration in preventing HF hospitalization, a further study involving influenza vaccine among HF patients is strongly recommended.

Competing Interests

The authors declare no competing interests in this work.

References

[1] B. C. G. Vooroudw, P. D. van der Linden, S. Simonian, J. van der Lei, M. C. J. M. Sturkenboom, and B. H. C. Stricker, “Influenza vaccination in community-dwelling elderly,” Archives of Internal Medicine, vol. 163, no. 9, pp. 1089–1094, 2003.

[2] R. Praditsuwan, P. Assantachai, C. Wasi, P. Puthavatana, and U. Kositanont, “The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community,” Journal of the Medical Association of Thailand, vol. 88, no. 2, pp. 256–264, 2005.

[3] T. Jefferson, D. Rivetti, A. Rivetti, M. Rudin, C. Di Pietrantoni, and V. Demicheli, “Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review,” The Lancet, vol. 366, no. 9492, pp. 1165–1174, 2005.

[4] J. Nordin, J. Mulloly, S. Poblete et al., “Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans,” Journal of Infectious Diseases, vol. 184, no. 6, pp. 665–670, 2001.

[5] T. Jefferson, C. Di Pietrantoni, L. A. Al-Ansary, E. Ferroni, S. Thorning, and R. E. Thomas, “Vaccines for preventing influenza in the elderly,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD004876, 2010.
[6] K. L. Nichol, J. D. Nordin, D. B. Nelson, J. P. Mullooly, and E. Hak, "Effectiveness of influenza vaccine in the community-dwelling elderly," The New England Journal of Medicine, vol. 357, no. 14, pp. 1373–1381, 2007.

[7] K. L. Nichol, J. Nordin, J. Mullooly, R. Lask, K. Fillbrandt, and M. Iwane, "Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly," The New England Journal of Medicine, vol. 348, no. 14, pp. 1322–1332, 2003.

[8] A. Vila-Córcoles, T. Rodríguez, C. de Diego et al., "Effect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002–2005 influenza periods," Vaccine, vol. 25, no. 37-38, pp. 6699–6707, 2007.

[9] A. Phrommintikul, S. Kuanprasert, W. Wongcharoen, R. Kanjanavanit, R. Chaiwarith, and A. Sukonthasarn, "Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome," European Heart Journal, vol. 32, no. 14, pp. 1730–1735, 2011.

[10] J. A. Udell, R. Zawi, D. L. Bhatt et al., "Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis," The Journal of the American Medical Association, vol. 310, no. 16, pp. 1711–1720, 2013.

[11] E. P. Gurfinkel, R. L. De La Fuente, O. Mendiz, and B. Mautner, "Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) study," Circulation, vol. 105, no. 18, pp. 2143–2147, 2002.

[12] E. Gurfinkel, "Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study One-year follow-up," European Heart Journal, vol. 25, no. 1, pp. 25–31, 2004.

[13] A. Ciszewski, Z. T. Bilinska, A. Sifile et al., "The comparison of antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study," American Journal of Kidney Diseases, vol. 54, no. 1, pp. 112–121, 2009.

[14] M. J. C. Salles, Y. A. S. Sens, L. S. V. Boas, and C. M. Machado, "Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs," Clinical Transplantation, vol. 24, no. 1, pp. E17–E23, 2010.

[15] C. Cavdar, M. Sayan, A. Sifile et al., "The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients," Scandinavian Journal of Urology and Nephrology, vol. 37, no. 1, pp. 71–76, 2003.

[16] A. Dvorakova and R. Poledne, "Influenza—a trigger for acute myocardial infarction," Atherosclerosis, vol. 172, no. 2, p. 391, 2004.

[17] M. Majdjid, M. Naghavi, S. Litovsky, and S. W. Casscells, "Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies," Circulation, vol. 108, no. 22, pp. 2730–2736, 2003.

[18] M. Naghavi, P. Wyde, S. Litovsky et al., "Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice," Circulation, vol. 107, no. 5, pp. 762–768, 2003.

[19] S. E. Epstein, J. Zhu, A. H. Najafi, and M. S. Burnett, "Insights into the role of infection in atherogenesis and in plaque rupture," Circulation, vol. 119, no. 24, pp. 3133–3141, 2009.

[20] M. Haidari, P. R. Wyde, S. Litovsky et al., "Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice," Atherosclerosis, vol. 208, no. 1, pp. 90–96, 2010.

[21] V. E. Corrales-Medina, M. Majdjid, and D. M. Mushser, "Role of acute infection in triggering acute coronary syndromes," The Lancet Infectious Diseases, vol. 10, no. 2, pp. 83–92, 2010.

[22] C. Warren-Gash, L. Smeeth, and A. C. Hayward, "Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review," The Lancet Infectious Diseases, vol. 9, no. 10, pp. 601–610, 2009.

[23] R. Brame, L. L. Mazerolle, and A. Piquero, "Using the correct statistical test for the equality of regression coefficients," Criminology, vol. 36, no. 4, pp. 859–866, 1998.

[24] O. Vardeny, J. M. Moran, N. K. Sweitzer, M. R. Johnson, and M. H. Hayney, "Decreased T-cell responses to influenza vaccination in patients with heart failure," Pharmacotherapy, vol. 30, no. 1, pp. 10–16, 2010.

[25] C. M. Albrecht, N. K. Sweitzer, M. R. Johnson, and O. Vardeny, "Lack of persistence of influenza vaccine antibody titers in patients with heart failure," Journal of Cardiac Failure, vol. 20, no. 2, pp. 105–109, 2014.

[26] O. Vardeny, N. K. Sweitzer, M. A. Detry, J. M. Moran, M. R. Johnson, and M. H. Hayney, "Decreased immune responses to influenza vaccination in patients with heart failure," Journal of Cardiac Failure, vol. 15, no. 4, pp. 368–373, 2009.

[27] E. Gurfinkel, R. L. DeLaFuente, O. Mendiz, and B. Mautner, "Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) study," Circulation, vol. 105, no. 18, pp. 2143–2147, 2002.

[28] E. Gurfinkel, "Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study One-year follow-up," European Heart Journal, vol. 25, no. 1, pp. 25–31, 2004.

[29] A. Ciszewski, Z. T. Bilinska, L. B. Brydak et al., "Influenza vaccine in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study," European Heart Journal, vol. 29, no. 11, pp. 1350–1358, 2008.

[30] M. M. Davis, K. Taubert, A. L. Benin et al., "Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology," Journal of the American College of Cardiology, vol. 48, no. 7, pp. 1498–1502, 2006.

[31] S. C. Smith, E. J. Benjamin, R. O. Bonow et al., "AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation," Circulation, vol. 124, no. 22, pp. 2458–2473, 2011.

[32] P. T. O’Gara, F. G. Kushner, D. D. Ascheim et al., "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Journal of the American College of Cardiology, vol. 61, no. 4, pp. e78–e140, 2013.

[33] R. S. Wright, J. L. Anderson, C. D. Adams et al., "2012 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable Angina/Non–ST-elevation myocardial infarction," Journal of the American College of Cardiology, vol. 61, no. 23, pp. e179–e437, 2013.

[34] C. W. Yancy, M. Jessup, B. Bozkurt et al., "2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines," Journal of the American College of Cardiology, vol. 62, no. 16, pp. e147–e239, 2013.

[35] J. Scharpé, W. E. Peetermans, J. Vanwalleghem et al., "Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial," American Journal of Kidney Diseases, vol. 54, no. 1, pp. 77–85, 2009.

[36] K. A. Birdwell, M. R. Ikizler, E. C. Sannella et al., "Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study," American Journal of Kidney Diseases, vol. 54, no. 1, pp. 112–121, 2009.

[37] M. J. C. Salles, Y. A. S. Sens, L. S. V. Boas, and C. M. Machado, "Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs," Clinical Transplantation, vol. 24, no. 1, pp. E17–E23, 2010.
[34] K. M. K. Grebe, K. Takeda, H. D. Hickman et al., “Cutting edge: sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis,” Journal of Immunology, vol. 184, no. 2, pp. 540–544, 2010.

[35] K. M. Grebe, H. D. Hickman, K. R. Irvine, K. Takeda, J. R. Bennink, and J. W. Yewdell, "Sympathetic nervous system control of anti-influenza CD8+ T cell responses," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 13, pp. 5300–5305, 2009.

[36] A. J. McMichael, F. M. Gotch, G. R. Noble, and P. A. S. Beare, "Cytotoxic T-cell immunity to influenza," The New England Journal of Medicine, vol. 309, no. 1, pp. 13–17, 1983.

[37] M. Montminy, "Transcriptional regulation by cyclic AMP," Annual Review of Biochemistry, vol. 66, pp. 807–822, 1997.

[38] O. Kanemi, X. Zhang, Y. Sakamoto, M. Ebina, and R. Nagatomi, "Acute stress reduces intraparenchymal lung natural killer cells via beta-adrenergic stimulation," Clinical and Experimental Immunology, vol. 139, no. 1, pp. 25–34, 2005.

[39] A. Rudiger, "Beta-block the septic heart," Critical Care Medicine, vol. 38, no. 10, pp. S608–S612, 2010.

[40] J. López-Sendón, K. Swedberg, and J. McMurray, “Expert consensus document on beta-adrenergic receptor blockers,” European Heart Journal, vol. 25, no. 15, pp. 1341–1362, 2004.

[41] I. J. V. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 33, no. 14, pp. 1787–1847, 2012.

[42] C. W. Hamm, J.-P. Bassand, S. Agewall et al., “ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevatio,” European Heart Journal, vol. 32, no. 23, pp. 2999–3054, 2011.

[43] I. J. Elenkov, R. L. Wilder, G. P. Chrousos, and E. S. Vizi, “The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system,” Pharmacological Reviews, vol. 52, no. 4, pp. 595–638, 2000.